5 Insightful Analyst Questions From NeoGenomics's Q1 Earnings Call

NeoGenomics’ first quarter results saw revenue growth, but sales came in below market expectations, leading to a significant negative market reaction. Management attributed the quarter’s performance to strong clinical test volume growth and increased adoption of next-generation sequencing (NGS) products, partially offset by continued headwinds in the non-clinical pharma segment. CEO Tony Zook described the quarter as confirming existing strengths, highlighting, “The NGS growth above market…was confirmatory for me coming in.” Management also noted that new product launches and the expansion of the commercial sales force were key operational focuses.

Is now the time to buy NEO? Find out in our full research report (it’s free).

While we enjoy listening to the management's commentary, our favorite part of earnings calls are the analyst questions. Those are unscripted and can often highlight topics that management teams would rather avoid or topics where the answer is complicated. Here is what has caught our attention.

Our Top 5 Analyst Questions NeoGenomics’s Q1 Earnings Call

• Andrew Brackman (William Blair) asked CEO Tony Zook about his early impressions as CEO and whether any business areas required more attention; Zook responded that recent performance largely confirmed his prior expectations, citing no major surprises.
• Dan Brennan (TD Cowen) questioned CFO Jeff Sherman on the outlook for the struggling pharma segment and the timing of Pathline’s revenue contribution. Sherman clarified that pharma would likely see another annual decline, with Pathline integration ramping gradually through 2025.
• Tejas Savant (Morgan Stanley) requested details on the company’s capital flexibility following convertible note repayments. Sherman explained that free cash flow is expected to turn positive in 2026, supporting continued investment and potential future M&A.
• Matthew Sykes (Goldman Sachs) asked about trends in average revenue per test. Sherman noted that test mix, especially from lower-priced Pathline business, will dilute near-term averages but that higher-value modalities like NGS continue to trend upward.
• David Westenberg (Piper Sandler) inquired about the sales force’s productivity ramp. President and COO Warren Stone indicated that full productivity is typically reached in 6–9 months, with most recent hires expected to contribute meaningfully in the second half of the year and into 2026.

Catalysts in Upcoming Quarters

Looking ahead, the StockStory team will be watching (1) the commercial launch and physician adoption rates of PanTracer liquid biopsy and tissue tests, (2) the pace and success of Pathline integration and cross-selling efforts in the Northeast, and (3) stabilization or improvement in the pharma segment amid ongoing macro headwinds. Execution on new commercial partnerships and operational efficiencies will also be important indicators.

NeoGenomics currently trades at $7.21, down from $9.97 just before the earnings. At this price, is it a buy or sell? The answer lies in our full research report (it’s free).

Our Favorite Stocks Right Now

Market indices reached historic highs following Donald Trump’s presidential victory in November 2024, but the outlook for 2025 is clouded by new trade policies that could impact business confidence and growth.

While this has caused many investors to adopt a "fearful" wait-and-see approach, we’re leaning into our best ideas that can grow regardless of the political or macroeconomic climate. Take advantage of Mr. Market by checking out our Top 5 Strong Momentum Stocks for this week. This is a curated list of our High Quality stocks that have generated a market-beating return of 183% over the last five years (as of March 31st 2025).

Stocks that made our list in 2020 include now familiar names such as Nvidia (+1,545% between March 2020 and March 2025) as well as under-the-radar businesses like the once-small-cap company Exlservice (+354% five-year return). Find your next big winner with StockStory today.